Thursday - October 30, 2025
AstraZeneca: Airsupra U.S. Prescribing Information Updated to Reflect the Statistically Significant Severe Exacerbation Risk Reduction in Patients With Mild Asthma Compared With Albuterol
September 19, 2025
WILMINGTON, Delaware, Sept. 19 (TNSjou) -- AstraZeneca, a biopharmaceutical company, issued the following news release:

* * *

AIRSUPRA (albuterol/budesonide) US prescribing information updated to reflect the statistically significant severe exacerbation risk reduction in patients with mild asthma compared with albuterol

The US Food and Drug Administration (FDA) has approved a supplemental

new drug application (sNDA) for AIRSUPRA

* . . .

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Name:
What's your
Affiliation		 Government Newspaper / Media Business
Public Policy Individual / Student Educators
Email:
Phone:
Organization, if any:
State/Country you are in:
Additonal questions
or comments:

Click here for more information about our products

Click here for more information about our products